The five largest funding rounds raised by Seattle tech companies totaled $196.5 million in November, up from the $133 million raised in October. This fresh capital went to advance solutions across various industries, including blockchain, biotech and aerospace. Read on to see which local companies are hiring and what they plan to do next.
Largest Seattle Tech Funding Rounds, November 2022
- Bonum Therapeutics
- MotherDuck
- Curevo
- Gravitics
- Notifi
5. Notifi: $10 million, November 9
Notifi provides software development kits that allow blockchain developers to send email and text notifications to users on their platform. With the oversubscribed seed round, Notifi plans to expand its tools beyond the Solana, NEAR and Ethereum blockchains to Polygon, Aptos Avalanche and Sui.
4. Gravitics: $20 million, November 17
The aerospace part manufacturer raised a $20 million seed round led by Type One Ventures. Seattle-based Gravitics said it will use the funding to build large modules for next-generation space stations. The module will provide up to 400 cubic meters of habitable space, which is half the size of the International Space Station.
3. Curevo: $26 million, November 16
The Bothell-based clinical-stage biotech company aims to reduce the number of infectious diseases by developing highly effective vaccines. Curevo is starting with the development of a vaccine to treat shingles. The Series A1 round included participation from Adjuvant Capital, Janus Henderson Investors and others.
2. MotherDuck: $47.5 million, November 15
After raising $47.5 million across a Series A round led by Andreessen Horowitz and a seed round from Redpoint, MotherDuck plans to expand its engineering and go-to-market teams. The Seattle-based data analytics company offers a serverless solution based on open-source database DuckDB.
1. Bonum Therapeutics: $93 million, November 15
Biopharmaceutical company Bonum Therapeutics aims to make less toxic, targeted and highly active medicines. The Seattle-based company was founded in 2022 and is a spinout of Good Therapeutics, which was acquired in August by Roche. Bonum’s Series A funding round will help the company apply its tech, which makes the development and engineering of a broad range of medicines possible, to regulated cytokines.
